{"id":2199,"date":"2026-06-09T11:00:00","date_gmt":"2026-06-09T14:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2199"},"modified":"2026-06-09T11:00:00","modified_gmt":"2026-06-09T14:00:00","slug":"rss-clinica-medicina-infectologia-hiv-tb-hepatite-b-c-sifilis-hpv-ist-tarv-prep","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/rss-clinica-medicina-infectologia-hiv-tb-hepatite-b-c-sifilis-hpv-ist-tarv-prep\/","title":{"rendered":"RSS infectologia: HIV, TB, hep B\/C, HPV"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de infectologia que reduzem RSS a descarte de seringa e gaze<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de infectologia<\/strong> + HIV+TARV terapia antirretroviral+PrEP+PEP<\/strong> + TB tuberculose pulmonar+extra-pulmonar+MDR+XDR<\/strong> + hepatite B+C+DAA antivirais a\u00e7\u00e3o direta<\/strong> + s\u00edfilis prim\u00e1ria+secund\u00e1ria+terci\u00e1ria+latente<\/strong> + HPV alto risco+oncog\u00eanico+vacina Gardasil 9<\/strong> + gonorreia+clam\u00eddia+herpes+IST resistente<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (sangue HIV+ + HBV+ + HCV+ + Treponema+) + Grupo A2 (secre\u00e7\u00e3o respirat\u00f3ria TB BAAR + secre\u00e7\u00e3o vaginal HPV + les\u00e3o s\u00edfilis prim\u00e1ria) + Grupo B (TARV antirretroviral + DAA antiviral hepatite + antibi\u00f3tico TB Listas A1\/B\/C5) + Grupo E (perfuro bi\u00f3psia + agulha core + Vacutainer). A consequ\u00eancia \u00e9 a pr\u00e1tica de cl\u00ednicas que otimizam apenas para sangue venoso<\/strong> + ignoram especificidades infectol\u00f3gicas + biosseguran\u00e7a BSL-3<\/strong> + subdimensionam fluxo BAAR TB+MDR+XDR<\/strong> + perdem rastreabilidade IST+vigil\u00e2ncia<\/strong>. A realidade \u00e9 exatamente o oposto. RSS infectologia opera em 5 fluxos infectol\u00f3gicos<\/strong> \u2014 HIV (TARV + PrEP + PEP + carga viral + CD4 + genotipagem), TB (BAAR + GeneXpert + cultura + PFP + MDR + XDR + bedaquilina + delamanida), hepatite B\/C (DAA Sofosbuvir+Ledipasvir+Glecaprevir+Pibrentasvir+Velpatasvir + tenofovir+entecavir B + transplante hep\u00e1tico), s\u00edfilis (penicilina G benzatina + cardiolipina + trepon\u00eamico + neurol\u00f3gico LCR), HPV+IST (Gardasil 9 + colposcopia + LEEP + condiloma + ceftriaxona+azitromicina+doxiciclina+aciclovir).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de infectologia, \u00e9 fundamental dimensionar RSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos infectol\u00f3gicos<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o RSS infectologia tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
HIV+TARV+PrEP\/PEP<\/td>\n4-12 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nCD4+CV+geno<\/td>\n<\/tr>\n
TB BAAR+GeneXpert<\/td>\n3-9 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nBSL-3+MDR\/XDR<\/td>\n<\/tr>\n
Hep B\/C+DAA<\/td>\n2-6 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nSofos+Glecap+Vel<\/td>\n<\/tr>\n
S\u00edfilis+penicilina<\/td>\n1-3 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nLCR+trepon\u00eamico<\/td>\n<\/tr>\n
HPV+IST<\/td>\n2-5 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nGardasil 9+LEEP<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 12-35 kg\/dia<\/strong> em cl\u00ednica infectologia m\u00e9dia porte.<\/p>\n

HIV+TARV+PrEP+PEP: o est\u00e1gio retroviral<\/h2>\n

A primeira camada \u00e9 HIV. Padr\u00e3o setorial inclui (a) HIV diagn\u00f3stico<\/strong> com teste r\u00e1pido Determine+OraQuick + ELISA 4\u00aa gera\u00e7\u00e3o + Western Blot + carga viral RT-PCR Cobas+Abbott+Hologic + CD4 fluxocitometria + genotipagem resist\u00eancia; (b) TARV terapia antirretroviral<\/strong> com TDF tenofovir + 3TC lamivudina + DTG dolutegravir Tivicay + FTC emtricitabina + EFV efavirenz + RAL raltegravir Isentress + DRV\/r darunavir+ritonavir + BIC bictegravir Biktarvy + CAB cabotegravir Vocabria injet\u00e1vel LA + RPV rilpivirina Edurant; (c) PrEP Pre-Exposure Prophylaxis<\/strong> com TDF\/FTC Truvada VO di\u00e1rio + CAB-LA cabotegravir SC bimensal Apretude + lenacapavir Sunlenca SC bianual; (d) PEP Post-Exposure Prophylaxis<\/strong> com TDF\/3TC + DTG 28 dias + acidente perfurocortante profissional + viol\u00eancia sexual + UNGASS+UNAIDS metas 95-95-95; (e) descarte HIV<\/strong> com sangue HIV+ saco vermelho + perfuro Vacutainer + TARV antirretroviral Lista C5 + identifica\u00e7\u00e3o A1+B+CID Z21+B20-B24.<\/p>\n

Cl\u00ednica com HIV+TARV+PrEP+PEP madura escala diagn\u00f3stico precoce<\/strong> + ades\u00e3o TARV >95%<\/strong> + suprime CV<50 c\u00f3pias\/mL<\/strong>. Como discutimos no post sobre PGRSS hospitalar<\/a>, HIV \u00e9 integrado.<\/p>\n

TB BAAR+GeneXpert+MDR\/XDR: o est\u00e1gio bacilo<\/h2>\n

A segunda camada \u00e9 TB. Padr\u00e3o setorial inclui (a) TB diagn\u00f3stico<\/strong> com BAAR Bacilo \u00c1lcool-\u00c1cido Resistente Ziehl-Neelsen + auramina-rodamina + GeneXpert MTB\/RIF Cepheid + cultura Lowenstein-Jensen + Bactec MGIT 960 BD + PFP teste antibiograma + IGRA QuantiFERON-TB Gold; (b) TB tratamento DOTS<\/strong> com RHZE rifampicina+isoniazida+pirazinamida+etambutol 2 meses fase intensiva + RH 4 meses fase manuten\u00e7\u00e3o + 6 meses total; (c) TB MDR multidrug-resistant<\/strong> com bedaquilina Sirturo Janssen + delamanida Deltyba Otsuka + linezolida Zyvox + clofazimina + cycloserina + 18-24 meses BPaL bedaquilina+pretomanida+linezolida; (d) TB XDR extensively drug-resistant<\/strong> com BPaLM bedaquilina+pretomanida+linezolida+moxifloxacina + 6 meses + cura 90%; (e) descarte TB+BAAR<\/strong> com saco vermelho BSL-3 biosseguran\u00e7a + cabine BSC Classe II A2 + aerossol-resistente + autoclave 121\u00b0C 30min + identifica\u00e7\u00e3o A2+BAAR+CID A15-A19.<\/p>\n

Cl\u00ednica com TB+GeneXpert+MDR\/XDR madura escala diagn\u00f3stico molecular<\/strong> + trata MDR\/XDR BPaL\/BPaLM<\/strong> + previne transmiss\u00e3o BSL-3<\/strong>. Conex\u00e3o com biosseguran\u00e7a<\/a>.<\/p>\n

Hepatite B+C+DAA + s\u00edfilis + HPV: o est\u00e1gio cr\u00f4nico+IST<\/h2>\n

A terceira camada \u00e9 hep+s\u00edfilis+HPV. Padr\u00e3o setorial inclui (a) HCV DAA antivirais a\u00e7\u00e3o direta<\/strong> com Sofosbuvir Sovaldi + Ledipasvir Harvoni + Glecaprevir+Pibrentasvir Mavyret + Velpatasvir+Sofosbuvir Epclusa + Voxilaprevir+Velpatasvir+Sofosbuvir Vosevi + cura SVR-12 >95%; (b) HBV antiviral<\/strong> com tenofovir TDF Viread + entecavir Baraclude + adefovir + lamivudina + transplante hep\u00e1tico Mayo Clinic protocol; (c) s\u00edfilis<\/strong> com penicilina G benzatina Benzetacil 2,4 mU IM dose \u00fanica prim\u00e1ria\/secund\u00e1ria + 3 doses semanais latente\/terci\u00e1ria + ceftriaxona 2g IV 14d neuross\u00edfilis + VDRL+RPR cardiolipina + trepon\u00eamico FTA-ABS+TPHA+EIA+ELISA; (d) HPV+vacina Gardasil 9 nonavalente<\/strong> Merck 6\/11\/16\/18\/31\/33\/45\/52\/58 + Cervarix bivalente GSK + colposcopia + bi\u00f3psia LEEP + cone cl\u00e1ssico + condiloma podofilina + 5-FU + imiquimod Aldara; (e) outras IST<\/strong> com ceftriaxona+azitromicina gonorreia + doxiciclina clam\u00eddia + aciclovir+valaciclovir herpes simples + IST resistente Nei-AMR + UNAIDS+OMS targets 90-90-90.<\/p>\n

Cl\u00ednica com hep+s\u00edfilis+HPV madura escala cura HCV SVR>95%<\/strong> + previne neuross\u00edfilis<\/strong> + vacina Gardasil 9 cobertura \u226580%<\/strong>. Conex\u00e3o com Lista C5<\/a>.<\/p>\n

Tr\u00eas perfis de RSS por capacidade infectologia<\/h2>\n

Cl\u00ednica infectologia b\u00e1sica.<\/strong> 2 fluxos. Custo mensal R$ 9.000-26.000<\/strong> mas perda de TB+MDR+DAA+HPV.<\/p>\n

Cl\u00ednica infectologia m\u00e9dia.<\/strong> 3 fluxos. Custo mensal R$ 18.000-45.000<\/strong>, captura HIV+TB+hep.<\/p>\n

Cl\u00ednica infectologia completa 5 fluxos.<\/strong> HIV+TB+hep+s\u00edfilis+HPV + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 35.000-85.000<\/strong>, efic\u00e1cia 95%, ROI 800-2.500% via captura infectol\u00f3gica + DAA + Gardasil 9 + ades\u00e3o TARV.<\/p>\n

Os tr\u00eas erros que aparecem em infectologia<\/h2>\n

O primeiro \u00e9 a subdimensionamento BSL-3 TB+BAAR<\/strong>. Sem cabine BSC Classe II A2 + autoclave 121\u00b0C 30min + aerossol-resistente = risco transmiss\u00e3o profissional + viola\u00e7\u00e3o biosseguran\u00e7a.<\/p>\n

O segundo \u00e9 a mistura HIV+ + TB+ + hep+<\/strong>. Confunde rastreabilidade etiol\u00f3gica + impossibilita vigil\u00e2ncia epidemiol\u00f3gica + risco contamina\u00e7\u00e3o cruzada.<\/p>\n

O terceiro \u00e9 a falta de protocolo PEP p\u00f3s-acidente<\/strong>. Sem TDF\/3TC+DTG 28d dispon\u00edvel 24\/7 = risco soroconvers\u00e3o profissional + viola\u00e7\u00e3o NR-32 + risco trabalhista.<\/p>\n

A regula\u00e7\u00e3o de RSS infectologia no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com infectologia especializada como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com calend\u00e1rio 2026 de compliance<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A SBI Sociedade Brasileira Infectologia<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o RSS infectologia 5 fluxos completos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a HIV teste r\u00e1pido Determine+ELISA 4\u00aa+CV RT-PCR Cobas+CD4+geno+TARV TDF\/3TC\/DTG\/FTC\/EFV\/BIC Biktarvy+CAB-LA Vocabria+lenacapavir Sunlenca+PrEP Truvada+Apretude+PEP, TB BAAR Ziehl+GeneXpert MTB\/RIF Cepheid+Lowenstein+Bactec MGIT+IGRA+RHZE+bedaquilina Sirturo+delamanida Deltyba+linezolida+BPaL+BPaLM, hep DAA Sovaldi+Harvoni+Mavyret+Epclusa+Vosevi SVR>95%+TDF+entecavir, s\u00edfilis penicilina Benzetacil+ceftriaxona+VDRL+FTA-ABS+TPHA, HPV Gardasil 9+Cervarix+colposcopia+LEEP+cone+condiloma+IST gonorreia+clam\u00eddia+herpes+resistente.<\/p>\n","protected":false},"excerpt":{"rendered":"

RSS infectologia: HIV + TB + hep B\/C + s\u00edfilis + HPV. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2198,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2901,1986,2170,3032],"class_list":["post-2199","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-hepatite","tag-hiv","tag-infectologia","tag-tb"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2199"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2199\/revisions"}],"predecessor-version":[{"id":4323,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2199\/revisions\/4323"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2198"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}